Citadel Advisors
SYRS

Citadel Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Citadel Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-209,900
Closed -$48.2K – 15924
2024
Q4 		$48.2K Buy
209,900
+169,300
+417% +$203K ﹤0.01% 12436
2024
Q3 		$87.3K Buy
40,600
+30,200
+290% +$108K ﹤0.01% 11300
2024
Q2 		$53.7K Sell
10,400
-6,000
-37% -$31.5K ﹤0.01% 11680
2024
Q1 		$87.7K Buy
16,400
+7,256
+79% +$50.2K ﹤0.01% 11527
2023
Q4 		$71.2K Buy
+9,144
New +$31.3K ﹤0.01% 11366
2022
Q2 		– Sell
-2,560
Closed -$30K – 14333
2022
Q1 		$30K Buy
2,560
+1,070
+72% +$19.1K ﹤0.01% 13111
2021
Q4 		$49K Sell
1,490
-1,440
-49% -$58.3K ﹤0.01% 13263
2021
Q3 		$131K Sell
2,930
-3,780
-56% -$185K ﹤0.01% 12540
2021
Q2 		$366K Buy
6,710
+640
+11% +$37.9K ﹤0.01% 10785
2021
Q1 		$454K Buy
6,070
+3,120
+106% +$324K ﹤0.01% 9884
2020
Q4 		$320K Buy
+2,950
New +$269K ﹤0.01% 8963

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's SYRS Position: Q3 2024 in Review

Citadel Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 26,622 shares — an estimated $95.6K sold.

Citadel Advisors first reported a position in SYRS in Q3 2017 and held it in 13 quarters. The position peaked at $5.22M in Q1 2021. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Citadel Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,622 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $95.6K.
  • Citadel Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Citadel Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.22M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.